Compare Diageo plc (DEO) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Diageo plc vs GeneDx Holdings Corp — how do they compare? Diageo plc trades at $86.59 (market cap $47.67B), while GeneDx Holdings Corp trades at $67.59 (market cap $2.02B). The key difference: Diageo plc is far larger — about 23.6× GeneDx Holdings Corp's market cap, and Diageo plc pays a 2.3% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Diageo plc for 66 Days and GeneDx Holdings Corp for 19 Days on average.
| DEO | WGS | |
|---|---|---|
Market Cap | $47.67B | $2.02B |
Volume | 893,372 | 734,640 |
Sector | Consumer Staples | Health |
52-Week High | $102.14 | $167.51 |
52-Week Low | $72.47 | $34.51 |
Typical Hold Time | 66 Days | 19 Days |
Enterprise Value | $68.09B | $2.05B |
Dividend Yield | 2.3% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Diageo (DEO) trades at $86.82, up 2.47% with bullish technical signals and strong analyst support. The stock shows solid fundamentals with consistent earnings beats, a 15.82% ROE, and improving cash flow trends. Recent corporate developments include a new CFO appointment and marketing initiatives supporting brand strength amid ongoing US business restructuring.
The outlook remains positive with 49% analyst buy ratings and cost-saving initiatives driving margin improvement. Key risks include US market volatility and regulatory challenges in India. The stock presents a compelling turnaround story with valuation support at current levels.
GeneDx (WGS) trades at $68.50, down 0.04% with a bearish technical signal despite bullish oscillators showing oversold conditions. The company reported mixed Q2 2026 results with revenue of $114.4M beating expectations but net income margin remains negative at -23.4%. Recent developments include new product launches and positive analyst coverage with 91% buy ratings.
While analyst consensus targets $81.00 (18% upside), fundamental challenges persist with negative profitability metrics and high valuation multiples. The stock faces execution risks amid competitive genomics landscape, but operational improvements and testing volume growth provide potential catalysts for recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Diageo plc
Diageo is a global leader in beverage alcohol with an outstanding collection of brands including Johnnie Walker, Smirnoff, and Guinness. It operates a vast portfolio of spirits and beers across more than 180 countries.
Read more on DEO →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
